In this study, we hypothesized that targeting the genetic variability in PTGS2, ABCC4, HPGD, and SLCO2A1, main players in the PGE2 pathway, would enable the identification of susceptibility biomarkers for GC onset. The gene discussed is PTGS2; the disease is gastric cancer.